Published in Gynecol Oncol on December 03, 2009
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Death receptors as targets in cancer. Br J Pharmacol (2013) 1.24
Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One (2010) 1.11
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res (2011) 1.02
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer (2011) 0.92
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br J Cancer (2013) 0.90
Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. Ann Oncol (2012) 0.85
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells. Oncoscience (2014) 0.79
Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling. Oncotarget (2015) 0.78
Lesser-Known Molecules in Ovarian Carcinogenesis. Biomed Res Int (2015) 0.78
Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells. Cancer Cell Int (2012) 0.76
Glycyrrhetinic Acid inhibits cell growth and induces apoptosis in ovarian cancer a2780 cells. Adv Pharm Bull (2014) 0.75
4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation. Oncotarget (2016) 0.75
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Management of lung nodules detected by volume CT scanning. N Engl J Med (2009) 6.79
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med (2003) 3.15
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Metformin: taking away the candy for cancer? Eur J Cancer (2010) 2.68
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer (2012) 2.39
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med (2009) 2.12
Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol (2010) 2.12
Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol (2008) 2.03
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res (2010) 2.03
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol (2005) 2.01
Features of resolving and nonresolving indeterminate pulmonary nodules at follow-up CT: the NELSON study. Radiology (2013) 1.98
[Primary surgery by a gynecological oncologist improves the prognosis in patients with ovarian carcinoma]. Ned Tijdschr Geneeskd (2009) 1.97
TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev (2008) 1.94
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res (2013) 1.87
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol (2010) 1.84
Introduction of the implantable Doppler system did not lead to an increased salvage rate of compromised flaps: a multivariate analysis. Plast Reconstr Surg (2010) 1.82
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med (2007) 1.79
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol (2006) 1.79
High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol (2003) 1.77
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem (2007) 1.74
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70
Validation and prognosis of coronary artery calcium scoring in nontriggered thoracic computed tomography: systematic review and meta-analysis. Circ Cardiovasc Imaging (2013) 1.70
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association? Ann Surg Oncol (2006) 1.58
The insulin-like growth factor system and sarcomas. J Pathol (2009) 1.57
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2006) 1.57
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer (2006) 1.55
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol (2009) 1.53
TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res (2006) 1.52
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene (2004) 1.50
Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002) 1.50
Effect of nodule characteristics on variability of semiautomated volume measurements in pulmonary nodules detected in a lung cancer screening program. Radiology (2008) 1.46
Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta (2009) 1.45
Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.43
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest (2010) 1.43
Quality-of-life outcomes between mastectomy alone and breast reconstruction: comparison of patient-reported BREAST-Q and other health-related quality-of-life measures. Plast Reconstr Surg (2013) 1.43
Systematic screening for urinary incontinence in older women: who could benefit from it? Scand J Prim Health Care (2012) 1.42
Severity, not type, is the main predictor of decreased quality of life in elderly women with urinary incontinence: a population-based study as part of a randomized controlled trial in primary care. Health Qual Life Outcomes (2012) 1.41
Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept. Mol Imaging Biol (2011) 1.41
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
The effect of systematic screening of older women for urinary incontinence on treatment uptake: the URINO trial. Maturitas (2013) 1.39
Impact of urinary incontinence on sexual functioning in community-dwelling older women. J Sex Med (2014) 1.39
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res (2007) 1.37
ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res (2005) 1.37
Estimation and prediction in a multi-state model for breast cancer. Biom J (2006) 1.36
Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2003) 1.36
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol (2004) 1.31
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res (2003) 1.29
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res (2010) 1.27
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev (2004) 1.25
Saline contrast hysterosonography in abnormal uterine bleeding: a systematic review and meta-analysis. BJOG (2003) 1.24
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol (2005) 1.24
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23